Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration.
暂无分享,去创建一个
Xinguo Jiang | Qizhi Zhang | Jun Chen | Xin-guo Jiang | Jianhua Zhu | Jun Chen | Hongzhuan Chen | Bingxian Wu | Zheng-xing Rong | Xiaoling Gao | Hongzhuan Chen | Bingxian Wu | Qizhi Zhang | Jianhua Zhu | Weiwei Zhang | Zhengxin Rong | Weiwei Zhang | Xiaoling Gao
[1] J. Fahrenkrug. Vasoactive intestinal polypeptide: measurement, distribution and putative neurotransmitter function. , 1979, Digestion.
[2] I. Gozes,et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[3] Gary M Pollack,et al. Nasal drug administration: potential for targeted central nervous system delivery. , 2005, Journal of pharmaceutical sciences.
[4] Tushar K. Vyas,et al. Intranasal drug delivery for brain targeting. , 2005, Current drug delivery.
[5] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Mcculloch,et al. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. , 1980, The American journal of physiology.
[7] B. Jansson,et al. The influence of gellan gum on the transfer of fluorescein dextran across rat nasal epithelium in vivo. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[8] I. Kwon,et al. In Vivo Gene Transfer to the Mouse Nasal Cavity Mucosa Using a Stable Cationic Lipid Emulsion , 2000, Molecules and cells.
[9] V. Mutt,et al. Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.
[10] M. Alonso,et al. Stealth PLA-PEG Nanoparticles as Protein Carriers for Nasal Administration , 1998, Pharmaceutical Research.
[11] A. Fisher,et al. Choline analogs as potential tools in developing selective animal models of central cholinergic hypofunction. , 1980, Life sciences.
[12] Xin-guo Jiang,et al. Preparation, characterization and application of pyrene-loaded methoxy poly(ethylene glycol)–poly(lactic acid) copolymer nanoparticles , 2004 .
[13] R. Thorne,et al. Quantitative analysis of the olfactory pathway for drug delivery to the brain , 1995, Brain Research.
[14] Maria José Alonso,et al. Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport , 2002, Pharmaceutical Research.
[15] W. Frey,et al. Delivery of Neurotrophic Factors to the Central Nervous System , 2001, Clinical pharmacokinetics.
[16] M. Brewster,et al. The use of human nasal in vitro cell systems during drug discovery and development. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.
[17] Wei Lu,et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. , 2006, Biomaterials.
[18] R. Prassl,et al. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery. , 2007, Biochimica et biophysica acta.
[19] W. Banks,et al. Passage of vasoactive intestinal peptide across the blood–brain barrier , 2003, Peptides.
[20] L. Helmuth. Detangling Alzheimer's disease. New insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics. , 2003, Science of aging knowledge environment : SAGE KE.
[21] A. Fisher,et al. (±)-cis-2-Methyl-spiro(1,3-oxathiolane-5,3′) quinuclidine (AF102B): A new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats , 1989, Neuroscience Letters.
[22] L. Jarrard,et al. Behavioral and neurochemical effects of intraventricular AF64A administration in rats , 1984, Pharmacology Biochemistry and Behavior.
[23] H. Natsume,et al. Poly-L-Arginine Predominantly Increases the Paracellular Permeability of Hydrophilic Macromolecules Across Rabbit Nasal Epithelium in Vitro , 2003, Pharmaceutical Research.
[24] V. Lelièvre,et al. VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment , 1995, Molecular Neurobiology.
[25] C. Dong,et al. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. , 2007, The international journal of neuropsychopharmacology.
[26] J. Yuan,et al. Estimation of variance for AUC in animal studies. , 1993, Journal of pharmaceutical sciences.
[27] T. Getchell,et al. Lectin histochemical localization of galactose, N-acetylgalactosamine, and N-acetylglucosamine in glycoconjugates of the rat vomeronasal organ, with comparison to the olfactory and septal mucosae , 1994, Cell and Tissue Research.
[28] C. Lehr,et al. Lectin-mediated drug targeting: history and applications. , 2004, Advanced drug delivery reviews.
[29] Y. Rahman,et al. Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. , 1998, Journal of Alzheimer's disease : JAD.
[30] H. Jacobsson,et al. In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. , 1994, Nuclear medicine and biology.
[31] D. Olton,et al. Neurotrophic Strategies for Treating Alzheimer's Disease: Lessons from Basic Neurobiology and Animal Models a , 1993, Annals of the New York Academy of Sciences.
[32] L. Illum. Transport of drugs from the nasal cavity to the central nervous system. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] W. Couet,et al. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. , 2003, International journal of pharmaceutics.
[34] A. Vila,et al. Design of biodegradable particles for protein delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[35] G. Berger,et al. Glycoconjugate Expression in Normal Human Inferior Turbinate Mucosa: A Lectin Histochemical Study , 2005, American journal of rhinology.
[36] G. Glazner,et al. VIP Neurotrophism in the Central Nervous System: Multiple Effectors and Identification of a Femtomolar‐Acting Neuroprotective Peptide , 1998, Annals of the New York Academy of Sciences.
[37] J. Gobert,et al. Behavioural and histological effects of low concentrations of intraventricular AF64A. , 1989, European journal of pharmacology.
[38] D. Gurwitz,et al. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease. , 1991, The Journal of pharmacology and experimental therapeutics.
[39] F. Bloom,et al. Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: a possible regulatory mechanism for the local control of energy metabolism. , 1981, Proceedings of the National Academy of Sciences of the United States of America.